GSK3787 (GSK-3787; GSK 3787) is a novel, potent, selective and irreversible antagonist of PPARδ (Peroxisome proliferator-activated receptor δ) with important biological activity.

Rosiglitazone (HSDB-7555; BRL-49653; TDZ-01; TDZ01; trade name Avandia) is an approved antidiabetic drug of the thiazolidinedione class with antidiabetic properties and potential antineoplastic activity.

FH535 (FH-535; FH 535) is a novel and potent dual inhibitor of the Wnt/β-catenin and the PPAR (γ/δ) pathways with potential antitumor activity.

Oroxin A is a novel and potent bioactive compound.

Rosiglitazone maleate (TDZ01; HSDB-7555; TDZ-01; BRL-49653; trade name Avandia), the maleic acid salt form of rosiglitazone which is an approved anti-diabetic drug, is a thiazolidinedione-based antihyperglycaemic agent with antidiabetic properties and potential antineoplastic activity.

Rosiglitazone HCl (HSDB-7555; BRL-49653; TDZ-01; BRL49653), the hydrochloride salt of Rosiglitazone, is a potent antidiabetic/antihyperglycemic drug of the thiazolidinedione class with anti-inflammatory activities.

T0070907 (T-0070907; T 0070907) is a potent and selective PPARγ (Peroxisome proliferator-activated receptor γ) inhibitor with potential anti-inflammatory activity.

Astaxanthin is a naturally occurring red dietary carotenoid isolated from Haematococcus pluvialis and a keto-carotenoid that belongs to a larger class of chemical compounds known as terpenes (as a tetraterpenoid) built from five carbon precursors, isopentenyl diphosphate, and dimethylallyl diphosphate.

Pioglitazone (U-72107A; AD-4833; Actos; AD4833, U-72107E) is approved and thiazolidinedione-based anti-diabetic drug which acts as a selective PPARϒ (Peroxisome proliferator-activated receptor γ) agonist with hypoglycemic activity.

GW9662 (GW-9662; GW 9662) is an irreversible and selective inhibitor of PPAR (peroxisome proliferator-activated receptor) with potential anticancer activity.